Medivation Says Astellas Submits MAA To EMA For Enzalutamide - Quick Facts

Medivation: Interim Analysis For PREVAIL Trial Expected To Occur In 2013

Medivation Q4 Loss Widens

Medivation Q4 12 Earnings Conference Call At 4:30 PM ET

Trade MDVN now with

6/26/2012 7:11 PM ET

Medivation, Inc. (MDVN: Quote) and Astellas Pharma Inc. announced that Astellas has submitted a Marketing Authorisation Application or MAA to the European Medicines Agency or EMA for enzalutamide (formerly MDV3100) for the treatment of men with metastatic castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy.

Enzalutamide is an oral, once-daily investigational agent that is an androgen receptor signaling inhibitor. A New Drug Application or NDA has been submitted in the United States, where priority review of the compound has been requested.

Click here to receive FREE breaking news email alerts for MEDIVATION INC and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 81 Articles Next>>

Editors Pick

Stocks Close Modestly Lower After Lackluster Trading Day - U.S. Commentary

After showing a lack of direction throughout much of the session, stocks ended Monday's trading modestly lower. The slightly lower close on the day partly offset the strength that was seen in the markets last week. The major averages ended the day below the unchanged line but off their lows for the session.

Obama To Deliver Speech On Counterterrorism Policies, Use Of Drones

President Barack Obama reportedly plans to deliver a much-anticipated speech on Thursday outlining his administration's evolving counterterrorism policies. Multiple news sources cited a White House official as saying that Obama will address the use of drones and plans to close the detention facility at Guantanamo Bay in a speech at the National Defense University.

Immigration Officers Union Expresses Opposition To Senate Bill

A second union representing immigration enforcement officers has expressed opposition to the Senate version of comprehensive immigration reform legislation, arguing that the bill fails to address the "insurmountable bureaucracy" at the agency that oversees lawful immigration to the U.S.